Search
User Avatar Login
The Defender
  • Explore The Defender
  • Categories
    • CHD.TV
  • Explore CHD.TV
  • Archive
    • Resources
  • Explore Our Resources
  • CHD Bookstore
  • CHD Films
  • eBooks
    • Community
  • Explore Advocacy
  • Community
  • Advocacy Help
    • Science
  • Explore the Science Section
  • Science Library
  • Vaccines
  • Electromagnetic Radiation
    • Legal Justice
  • Explore Litigation
  • Learn The Law
    • About Us
  • About Children’s Health Defense
  • More from CHD
    • Vax-Unvax: Let The Science Speak Home › Citations

    Chapter 3

    This is a listing of all citations in this chapter.

    91

    David A. Geier et al., “Thimerosal Exposure and Disturbance of Emotions Specific to Childhood and Adolescence: A Case-Control Study in the Vaccine Safety Datalink (VSD) Database,” Brain Injury 31, no. 2 (2017): 272-278. doi:10.1080/02699052.2016.1250950.

    92

    David A. Geier et al., “Thimerosal-Containing Hepatitis B Vaccination and the Risk for Diagnosed Specific Delays in Development in the United States: A Case-Control Study in the Vaccine Safety Datalink,” North American Journal of Medical Sciences 6, no. 10 (2014): 519-531, doi:10.4103/1947-2714.143284.

    93

    David A. Geier et al., “A Two-Phase Study Evaluating the Relationship Between Thimerosal-Containing Vaccine Administration and the Risk for an Autism Spectrum Disorder Diagnosis in the United States,” Translational Neurodegeneration 2, no. 1 (2013): 25, doi:10.1186/2047-9158-2-25.

    94

    Heather A. Young, David A. Geier and Mark R. Geier, “Thimerosal Exposure in Infants and Neurodevelopmental Disorders: An Assessment of Computerized Medical Records in the Vaccine Safety Datalink,” Journal of the Neurological Sciences 271, no. 1-2 (2008): 110-118. doi:10.1016/j.jns.2008.04.002.

    95

    Thomas M. Verstraeten et al., “Increased Risk of Developmental Neurological Impairment After High Exposure to Thimerosal-Containing Vaccine in First Month of Life,” Epidemic Intelligence Service, accessed on September 24, 2022.

    96

    Heather A. Young, David A. Geier and Mark R. Geier, “Thimerosal Exposure in Infants and Neurodevelopmental Disorders: An Assessment of Computerized Medical Records in the Vaccine Safety Datalink,” Journal of the Neurological Sciences 271, no. 1-2 (2008): 110-118. doi:10.1016/j.jns.2008.04.002.

    97

    Heather A. Young, David A. Geier and Mark R. Geier, “Thimerosal Exposure in Infants and Neurodevelopmental Disorders: An Assessment of Computerized Medical Records in the Vaccine Safety Datalink,” Journal of the Neurological Sciences 271, no. 1-2 (2008): 110-118. doi:10.1016/j.jns.2008.04.002.

    98

    David A. Geier et al., “Thimerosal Exposure and Increased Risk for Diagnosed Tic Disorder in the United States: A Case-Control Study,” Interdisciplinary Toxicology 8, no. 2 (2015): 68-76, doi:10.1515/intox-2015-0011.

    99

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    100

    Nick Andrews et al., “Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association,” Pediatrics 114, no. 3 (2004): 584–591, doi:10.1542/peds.2003-1177-L.

    101

    William W. Thompson et al., “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years,” The New England Journal of Medicine 357, no. 13 (2007): 1281-1292. doi:10.1056/NEJMoa071434.

    102

    Carolyn M. Gallagher and Melody S. Goodman. 2010. “Hepatitis B Vaccination of Male Neonates and Autism Diagnosis, NHIS 1997-2002,” Journal of Toxicology and Environmental Health Part A 73, no. 24 (2010): 1665-167, doi:10.1080/15287394.2010.519317.

    103

    David A. Geier, Janet K. Kern and Mark R. Geier, “Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink,” Toxics 6, no. 4 (2018): 67, doi:10.3390/toxics6040067.

    104

    David A. Geier et al., “Thimerosal Exposure and Disturbance of Emotions Specific to Childhood and Adolescence: A Case-Control Study in the Vaccine Safety Datalink (VSD) Database,” Brain Injury 31, no. 2 (2017): 272-278. doi:10.1080/02699052.2016.1250950.

    105

    David A. Geier et al., “Thimerosal-Containing Hepatitis B Vaccination and the Risk for Diagnosed Specific Delays in Development in the United States: A Case-Control Study in the Vaccine Safety Datalink,” North American Journal of Medical Sciences 6, no. 10 (2014): 519-531, doi:10.4103/1947-2714.143284.

    106

    David A. Geier et al., “A Two-Phase Study Evaluating the Relationship Between Thimerosal-Containing Vaccine Administration and the Risk for an Autism Spectrum Disorder Diagnosis in the United States,” Translational Neurodegeneration 2, no. 1 (2013): 25, doi:10.1186/2047-9158-2-25.

    107

    David A. Geier, Janet K. Kern and Mark R. Geier, “Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink,” Toxics 6, no. 4 (2018): 67, doi:10.3390/toxics6040067.

    108

    David A. Geier et al., “Thimerosal Exposure and Disturbance of Emotions Specific to Childhood and Adolescence: A Case-Control Study in the Vaccine Safety Datalink (VSD) Database,” Brain Injury 31, no. 2 (2017): 272-278. doi:10.1080/02699052.2016.1250950.

    109

    David A. Geier et al., “Thimerosal-Containing Hepatitis B Vaccination and the Risk for Diagnosed Specific Delays in Development in the United States: A Case-Control Study in the Vaccine Safety Datalink,” North American Journal of Medical Sciences 6, no. 10 (2014): 519-531, doi:10.4103/1947-2714.143284.

    110

    David A. Geier et al., “A Two-Phase Study Evaluating the Relationship Between Thimerosal-Containing Vaccine Administration and the Risk for an Autism Spectrum Disorder Diagnosis in the United States,” Translational Neurodegeneration 2, no. 1 (2013): 25, doi:10.1186/2047-9158-2-25.